Cardiac Implantable Electronic Device Implantation

2015 ◽  
Vol 26 (4) ◽  
pp. 312-319 ◽  
Author(s):  
Melissa E. Harding
2021 ◽  
Author(s):  
Peter Magnusson ◽  
Jo Ann LeQuang ◽  
Joseph V. Pergolizzi

Postoperative pain following cardiac implantable electronic device (CIED) surgery may not always be adequately treated. The postoperative pain trajectory occurs over several days following the procedure with tenderness and limited arm range of motion lasting for weeks after surgery. Pain control typically commences in the perioperative period while the patient is in the hospital and may continue after discharge; outpatients may be given a prescription and advice for their analgesic regimen. It is not unusual for CIED patients to be discharged a few hours after implantation. While opioids are known as an effective analgesic to manage acute postoperative pain, growing scrutiny on opioid use as well as their side effects and potential risks have limited their use. Opioids may be considered for appropriate patients for a short course of treatment of acute postoperative pain, but other analgesics may likewise be considered.


EP Europace ◽  
2017 ◽  
Vol 19 (6) ◽  
pp. 1007-1014 ◽  
Author(s):  
Cengiz Özcan ◽  
Jakob Raunsø ◽  
Morten Lamberts ◽  
Lars Køber ◽  
Tommi Bo Lindhardt ◽  
...  

2020 ◽  
Vol 6 (6) ◽  
pp. 661-671 ◽  
Author(s):  
Varunsiri Atti ◽  
Mohit K. Turagam ◽  
Jalaj Garg ◽  
Scott Koerber ◽  
Aakash Angirekula ◽  
...  

Heart Rhythm ◽  
2020 ◽  
Vol 17 (11) ◽  
pp. 2010-2015 ◽  
Author(s):  
Naga Venkata K. Pothineni ◽  
C. Anwar A. Chahal ◽  
David S. Frankel ◽  
Fermin C. Garcia ◽  
Jay Giri ◽  
...  

2018 ◽  
Vol 1 (46) ◽  
pp. 17-23
Author(s):  
Paweł Basiukiewicz ◽  
Janusz Bednarski ◽  
Łukasz Pastwa ◽  
Anna Chudoba

Almost half of patients who underwent CIED implantation receive antiplatelet or anticoagulant agents. Despite the number of trials, also randomized perioperative management with antiplatelet/anticoagulant therapy differs between centers. Some of physicians withdraw antiplatelet or anticoagulant therapy because of risk of pocket haematoma that could lead to reintervention, while some of them continue antiplatelet/anticoagulant therapy without concerns or put patient on the bridging therapy with LMWH. This article is an attempt to summarize reports and recommendations concerning problem of antiplatelet and antitrombotic therapy in periprocedural CIED period.


Sign in / Sign up

Export Citation Format

Share Document